A comparison of the effects of citalopram and moclobemide on resting brain perfusion in social anxiety disorder
- 180 Downloads
Introduction: The serotonin specific reuptake inhibitor (SSRI) citalopram and the reversible mono-amine oxidase-A inhibitor (RIMA) moclobemide have both been used successfully for the treatment of social anxiety disorder (SAD). In this study we investigate the effects of these compounds on resting brain function using single photon emission computed tomography (SPECT).
Methods: Subjects meeting DSM-IV criteria for SAD underwent regional cerebral blood flow (rCBF) SPECT using Tc-HMPAO at baseline and after 8 weeks of treatment with either citalopram or moclobemide. Using statistical parametric mapping brain SPECT studies were analysed to determine the effects of treatment on rCBF, to compare the effects of citalopram and moclobemide, and to detect correlations between changes in rCBF and clinical response.
Results: Subjects received citalopram (n=17) or moclobemide (n=14) as therapy. Subjects in both treatment groups demonstrated a significant improvement of SAD symptoms as measured by the Liebowitz Social Anxiety Scale total score. All subjects demonstrated a decrease in rCBF in the insulae post therapy. Subjects receiving citalopram had decreased superior cingulate rCBF after therapy compared to those receiving moclobemide.
Conclusion: Both SSRI's and RIMA's decreased rCBF in the insulae during treatment of SAD; an effect that may be consistent with the role of these regions in processing internal somatic cues evoked by emotional stimuli. Citalopram had a greater effect on superior cingulate perfusion, an effect that is consistent with evidence of high levels of 5-HT transporters in this region.
KeywordsSocial phobia SPECT Citalopram Moclobemide Insula Cingulate
- American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington, DCGoogle Scholar
- Ballenger JC (1998) Focus on social anxiety disorder. J Clin Psychiatry 59(suppl. 17):3Google Scholar
- Deakin JWF et al (1991) J Psychopharmacol 5:305–315Google Scholar
- de Win MM, Habraken JB, Reneman L, van den Brink W, den Heeten GJ, Booij J (2005) Validation of [(123)I]beta-CIT SPECT to assess serotonin transporters in vivo in humans: a double-blind, placebo-controlled, crossover study with the selective serotonin reuptake inhibitor citalopram. Neuropsychopharmacology 30:996–1005PubMedCrossRefGoogle Scholar
- First MB, Spitzer RL, Gibbon M, Williams JBW (1996) Structured Clinical Interview for DSM-IV Axis I Disorders—Clinician Edition. Biometrics Research Department, New York State Research Institute, NYGoogle Scholar
- Kent JM, Coplan JD, Lombardo I, Hwang D, Huang Y, Mawlawi O, Van Heertum RL, Slifstein M, Abi-Dargham A, Gorman JM, Laruelle M (2002) Occupancy of brain serotonin transporters during treatment with paroxetine in patients with social phobia: a positron emission tomography study with [11C]McN 5652. Psychopharmacology 164:341–348PubMedCrossRefGoogle Scholar
- Liebowitz MR (1987) Social Phobia. Mod Probl Pharmacopsychiat 22:141–173Google Scholar
- Lorderbaum JP, Kose S, Johnson MR, Arana GW, Sullivan LK, Hamner MB, Ballenger JC, Lydiard RB, Brodrick PS, Bohning DE, George MS (2004) Neural correlates of speech anticipatory anxiety in generalised social phobia. Neuroreport 15:2701–2705Google Scholar
- Sheehan D (1983) The anxiety disease, Scribners, New YorkGoogle Scholar
- Smith GS, Kramer E, Hermann CR, Goldberg S, Ma Y, Dhawan V, Barnes A, Chaley T, Belakhleff A, Laghrissi-Thode F, Greenwald B, Eidelberg D, Pollock BG (2002) Acute and chronic effects of citalopram on cerebral glucose metabolism in geriatric depression. Am J Geriatr Psychiatry 10:715–723PubMedCrossRefGoogle Scholar
- Van der Linden G, Van Heerden B, Warwick J, Wessels C, Van Kradenburg J, Zungu-Dirwayi N, Stein DJ (2000) Functional brain imaging and pharmacotherapy in social phobia: single photon emission computed tomography before and after treatment with the selective serotonin reuptake inhibitor citalopram. Prog Neuro-psychopharmacol and Biol Psychiat 24:419–438CrossRefGoogle Scholar